Q-omics provides the consensus-scored BIN3 profile across patient tissues and cancer cell-line models. BIN3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BIN3 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, BIN3 protein abundance shows 26,511 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, THCA, and BRCA as cancer lineages where BIN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BIN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BIN3 survival associations across molecular data types. BIN3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BIN3 RNA expression–survival associations across cancer types. High BIN3 expression shows unfavorable associations in KICH and LGG, but favorable associations in BLCA, BRCA, HNSC and READ. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BIN3 RNA expression.
This table summarizes BIN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BIN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BIN3 shows lower tumor expression in THCA, KICH, BRCA and LUAD and higher tumor expression in CHOL and STAD. The THCA box plot shows higher BIN3 RNA expression in normal versus tumor tissue (log2 FC = −0.243, t-test p < 0.001).
This table shows molecular features associated with BIN3 in patient tissues and cancer cell lines. In patient samples, BIN3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BIN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
